Enveric Biosciences, a biotechnology company developing next-generation small-molecule neuroplastogenic therapeutics, announced the issuance of a significant new U.S. patent that enhances its intellectual property portfolio and expands opportunities for advancing treatments in mental health disorders.
The newly granted U.S. Patent No. 12,492,179, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives,” covers a novel class of compounds with potential applications in treating neuropsychiatric and neurological conditions. These proprietary molecules are designed to be neuroplastogenic and non-hallucinogenic, offering promising avenues for drug discovery in areas where effective therapies are limited.
According to the company, this patent not only broadens the scope of its protected pipeline but also strengthens Enveric’s positioning to develop or license new therapeutic candidates that interact with key neural receptors in ways that may achieve improved safety and efficacy profiles. The expanded intellectual property estate also enhances the company’s appeal to pharmaceutical partners and investors interested in the rapidly evolving neuropsychiatric drug space.
Joseph Tucker, Ph.D., Director and CEO of Enveric, highlighted that the growing portfolio of patented molecules underscores the company’s commitment to innovation in mental health treatment and positions the firm for continued strategic growth within the biotech industry.
Enveric’s research focus includes a differentiated drug discovery platform and a pipeline of compounds engineered to promote neuroplasticity without hallucinogenic effects — a key differentiator in the development of novel therapies for disorders such as depression, anxiety, addiction, and other neuropsychiatric conditions.
